Annual EBITDA
-$51.16 M
+$16.13 M+23.97%
31 December 2023
Summary:
Verona Pharma annual earnings before interest, taxes, depreciation & amortization is currently -$51.16 million, with the most recent change of +$16.13 million (+23.97%) on 31 December 2023. During the last 3 years, it has risen by +$13.18 million (+20.49%). VRNA annual EBITDA is now -426241.67% below its all-time high of -$12.00 thousand, reached on 31 December 2005.VRNA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$32.56 M
+$35.23 M+51.97%
30 September 2024
Summary:
Verona Pharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$32.56 million, with the most recent change of +$35.23 million (+51.97%) on 30 September 2024. Over the past year, it has dropped by -$18.48 million (-131.16%). VRNA quarterly EBITDA is now -385.00% below its all-time high of $11.43 million, reached on 30 September 2021.VRNA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$136.90 M
-$18.48 M-15.60%
30 September 2024
Summary:
Verona Pharma TTM earnings before interest, taxes, depreciation & amortization is currently -$136.90 million, with the most recent change of -$18.48 million (-15.60%) on 30 September 2024. Over the past year, it has dropped by -$89.05 million (-186.11%). VRNA TTM EBITDA is now -10987.06% below its all-time high of -$1.23 million, reached on 30 June 2016.VRNA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRNA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.0% | -131.2% | -186.1% |
| 3 y3 years | +20.5% | -385.0% | -144.7% |
| 5 y5 years | -68.5% | -110.5% | -222.0% |
VRNA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +24.0% | -385.0% | +52.0% | -186.1% | at low |
| 5 y | 5 years | -68.5% | +24.0% | -385.0% | +52.0% | -256.6% | at low |
| alltime | all time | <-9999.0% | +24.0% | -385.0% | +52.0% | <-9999.0% | at low |
Verona Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$32.56 M(-52.0%) | -$136.90 M(+15.6%) |
| June 2024 | - | -$67.79 M(+192.3%) | -$118.43 M(+103.4%) |
| Mar 2024 | - | -$23.19 M(+73.7%) | -$58.23 M(+13.8%) |
| Dec 2023 | -$51.16 M(-24.0%) | -$13.35 M(-5.2%) | -$51.16 M(+6.9%) |
| Sept 2023 | - | -$14.09 M(+85.4%) | -$47.85 M(-2.5%) |
| June 2023 | - | -$7.60 M(-52.9%) | -$49.07 M(-16.7%) |
| Mar 2023 | - | -$16.12 M(+60.5%) | -$58.90 M(-12.5%) |
| Dec 2022 | -$67.29 M(+23.2%) | -$10.04 M(-34.4%) | -$67.29 M(-16.4%) |
| Sept 2022 | - | -$15.31 M(-12.2%) | -$80.51 M(+49.7%) |
| June 2022 | - | -$17.43 M(-28.9%) | -$53.78 M(-7.5%) |
| Mar 2022 | - | -$24.51 M(+5.3%) | -$58.15 M(+6.5%) |
| Dec 2021 | -$54.62 M(-15.1%) | -$23.27 M(-303.6%) | -$54.62 M(-2.4%) |
| Sept 2021 | - | $11.43 M(-152.4%) | -$55.96 M(-35.0%) |
| June 2021 | - | -$21.81 M(+4.0%) | -$86.11 M(+17.7%) |
| Mar 2021 | - | -$20.97 M(-14.8%) | -$73.17 M(+13.7%) |
| Dec 2020 | -$64.34 M(+60.9%) | -$24.60 M(+31.4%) | -$64.34 M(+54.4%) |
| Sept 2020 | - | -$18.73 M(+111.2%) | -$41.66 M(+8.5%) |
| June 2020 | - | -$8.87 M(-26.9%) | -$38.39 M(-11.5%) |
| Mar 2020 | - | -$12.13 M(+531.0%) | -$43.38 M(+8.9%) |
| Dec 2019 | -$39.98 M | -$1.92 M(-87.6%) | -$39.83 M(-6.3%) |
| Sept 2019 | - | -$15.47 M(+11.6%) | -$42.51 M(+35.0%) |
| June 2019 | - | -$13.86 M(+61.4%) | -$31.48 M(+73.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$8.58 M(+86.2%) | -$18.11 M(-43.3%) |
| Dec 2018 | -$30.36 M(-10.2%) | -$4.61 M(+3.8%) | -$31.96 M(-16.8%) |
| Sept 2018 | - | -$4.44 M(+826.0%) | -$38.42 M(-19.7%) |
| June 2018 | - | -$479.40 K(-97.9%) | -$47.81 M(-9.3%) |
| Mar 2018 | - | -$22.43 M(+102.7%) | -$52.70 M(+57.7%) |
| Dec 2017 | -$33.79 M(+370.2%) | -$11.07 M(-20.0%) | -$33.41 M(+36.6%) |
| Sept 2017 | - | -$13.83 M(+158.0%) | -$24.46 M(+84.8%) |
| June 2017 | - | -$5.36 M(+70.7%) | -$13.24 M(+45.3%) |
| Mar 2017 | - | -$3.14 M(+47.9%) | -$9.11 M(+52.6%) |
| Dec 2016 | -$7.19 M(-45.4%) | -$2.12 M(-18.7%) | -$5.97 M(+55.2%) |
| Sept 2016 | - | -$2.61 M(+111.5%) | -$3.85 M(+211.5%) |
| June 2016 | - | -$1.23 M | -$1.23 M |
| Dec 2015 | -$13.17 M(+126.2%) | - | - |
| Dec 2014 | -$5.82 M(+27.0%) | - | - |
| Dec 2013 | -$4.58 M(+11.0%) | - | - |
| Dec 2012 | -$4.13 M(+45.8%) | - | - |
| Dec 2011 | -$2.83 M(-1.4%) | - | - |
| Dec 2010 | -$2.87 M(+12.6%) | - | - |
| Dec 2009 | -$2.55 M(+18.9%) | - | - |
| Dec 2008 | -$2.15 M(-16.2%) | - | - |
| Dec 2007 | -$2.56 M(+95.5%) | - | - |
| Dec 2006 | -$1.31 M(>+9900.0%) | - | - |
| Dec 2005 | -$12.00 K | - | - |
FAQ
- What is Verona Pharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Verona Pharma?
- What is Verona Pharma annual EBITDA year-on-year change?
- What is Verona Pharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Verona Pharma?
- What is Verona Pharma quarterly EBITDA year-on-year change?
- What is Verona Pharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Verona Pharma?
- What is Verona Pharma TTM EBITDA year-on-year change?
What is Verona Pharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of VRNA is -$51.16 M
What is the all time high annual EBITDA for Verona Pharma?
Verona Pharma all-time high annual earnings before interest, taxes, depreciation & amortization is -$12.00 K
What is Verona Pharma annual EBITDA year-on-year change?
Over the past year, VRNA annual earnings before interest, taxes, depreciation & amortization has changed by +$16.13 M (+23.97%)
What is Verona Pharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of VRNA is -$32.56 M
What is the all time high quarterly EBITDA for Verona Pharma?
Verona Pharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $11.43 M
What is Verona Pharma quarterly EBITDA year-on-year change?
Over the past year, VRNA quarterly earnings before interest, taxes, depreciation & amortization has changed by -$18.48 M (-131.16%)
What is Verona Pharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of VRNA is -$136.90 M
What is the all time high TTM EBITDA for Verona Pharma?
Verona Pharma all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.23 M
What is Verona Pharma TTM EBITDA year-on-year change?
Over the past year, VRNA TTM earnings before interest, taxes, depreciation & amortization has changed by -$89.05 M (-186.11%)